Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Pembrolizumab Plus Epacadostat, Pembrolizumab monoterapi og den EKSTERME kur ved tilbagevendende eller metastatisk hoved- og halspladecellecarcinom (KEYNOTE-669/ECHO-304)

4. september 2026 opdateret af: Incyte Corporation

Et fase 3 randomiseret, åbent klinisk studie til evaluering af effektiviteten og sikkerheden af ​​Pembrolizumab Plus Epacadostat, Pembrolizumab monoterapi og EXTREME regimen som førstelinjebehandling for recidiverende eller metastatisk hoved- og nakkepladecellecarcinom (KEYNOTE-6369/ECHO) )

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

89

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New South Wales
      • Camperdown, New South Wales, Australien, 2050
        • Chris OBrien Lifehouse
      • North Ryde, New South Wales, Australien, 2109
        • Macquarie University Hospital
    • Queensland
      • Herston, Queensland, Australien, 4029
        • Royal Brisbane & Women s Hospital
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Juravinski Cancer Center Hamilton Health Sciences
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret Cancer Centre
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Jewish General Hospital
      • Québec, Quebec, Canada, G1R 3S1
        • CHU de Quebec-Universite Laval-Hotel Dieu de Quebec
      • London, Det Forenede Kongerige, N18 1QX
        • North Middlesex Hospital
      • London, Det Forenede Kongerige, NW1 2PG
        • University College London Hospitals (UCLH)
      • London, Det Forenede Kongerige, SW3 6JJ
        • The Royal Marsden Foundation Trust
      • London, Det Forenede Kongerige, SW3 6JJ
        • The Royal Marsden Nhs Foundation Trust - Chelsea
      • Taunton, Det Forenede Kongerige, TA1 5DA
        • Musgrove Park Hospital
    • California
      • Anaheim, California, Forenede Stater, 19026
        • Pacific Cancer Medical Center
      • Sacramento, California, Forenede Stater, 95817
        • UC Davis Comprehensive Cancer Center
      • Santa Rosa, California, Forenede Stater, 95403
        • St. Joseph Heritage Healthcare
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • University of Colorado Cancer Center
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06520
        • Yale Cancer Center
    • Georgia
      • Douglasville, Georgia, Forenede Stater, 30134
        • Northwest Georgia Oncology Centers PC
    • Kansas
      • Westwood, Kansas, Forenede Stater, 66205
        • U of Kansas Cancer Center
    • Kentucky
      • Louisville, Kentucky, Forenede Stater, 40223
        • Baptist Health
    • Montana
      • Billings, Montana, Forenede Stater, 59102
        • St. Vincent Healthcare Cancer Ctr
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • New Mexico Cancer Care Alliance
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74146
        • Oklahoma Cancer Specialists and Research
    • Oregon
      • Portland, Oregon, Forenede Stater, 97213
        • Providence Portland Med Center
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 19026
        • Huntsman Cancer Institute Univ of Utah
    • Washington
      • Seattle, Washington, Forenede Stater, 98101
        • Viginia Mason Med Ctr
      • Milan, Italien, 20141
        • Istituto Europeo di Oncologia
      • Rozzano, Italien, 20089
        • IRRCS Instituto Clinico Humanitas
      • Akashi, Japan, 673-8558
        • Hyogo Cancer Center
      • Fukuoka, Japan, 812-8582
        • Kyushu University Hospital
      • Hiroshima, Japan, 734-8551
        • Hiroshima University Hospital
      • Hokkaido, Japan, 060-8648
        • Hokkaido University Hospital
      • Kobe, Japan, 650-0047
        • Kobe City Medical Center General Hospital
      • Saitama, Japan, 362-0806
        • Saitama Cancer Center
      • Sayama, Japan, 589-8511
        • Kindai University Hospital
      • Shizuoka, Japan, 411-8777
        • Shizuoka Cancer Center Hospital and Research Institute
      • Tokyo, Japan, 135-8550
        • The Cancer Institute Hospital of JFCR
    • Chiba
      • Kashiwa, Chiba, Japan, 277-8577
        • National Cancer Center Hospital East
    • Ishikawa-ken
      • Kanazawa, Ishikawa-ken, Japan, 920-8641
        • Kanazawa University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 241-8515
        • Kanagawa Cancer Center
    • Miyagi
      • Natori-shi, Miyagi, Japan, 981-1293
        • Miyagi Cancer Center
      • Sendai, Miyagi, Japan, 980-8574
        • Tohoku University Hospital
      • Konin, Polen, 62-500
        • Przychodnia Lekarska Komed
      • Szczecin, Polen, 71-730
        • Zachodniopomorskie Centrum Onkologii
    • Masovian Voivodeship
      • Wieliszew, Masovian Voivodeship, Polen, 05-135
        • Mazowiecki Szpital Onkologiczny
      • Coimbra, Portugal, 3000-075
        • Inst. Portugues de Oncologia de Coimbra Frencisco Gentil EPE
      • Lisbon, Portugal, 1099-023
        • Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE
      • Lisbon, Portugal, 1649-035
        • Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria
      • Porto, Portugal, 4200-072
        • Inst. Portugues de Oncologia de Porto Francisco Gentil EPE
      • Badalona, Spanien, 08916
        • Hospital Germans Trias i Pujol. ICO de Badalona
      • Barcelona, Spanien, 08035
        • Hospital General Universitari Vall d Hebron
      • Madrid, Spanien, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Spanien, 28034
        • Hospital Ramon y Cajal
      • Madrid, Spanien, 28981
        • Hospital Infanta Cristina
      • Seville, Spanien, 41014
        • Hospital de Nuestra Senora de Valme
      • Zaragoza, Spanien, 50009
        • Hospital Clinico Lozano Blesa
      • Seoul, Sydkorea, 03080
        • Seoul National University Hospital
      • Seoul, Sydkorea, 05505
        • Asan Medical Center
      • Seoul, Sydkorea, 03722
        • Severance Hospital Yonsei University Health System
      • Tainan, Taiwan, 70457
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 10048
        • National Taiwan University Hospital
      • Taoyuan, Taiwan, 33305
        • Chang Gung Medical Foundation. Linkou
      • Adana, Tyrkiet (Türkiye), 01370
        • Adana Sehir Hastanesi
      • Ankara, Tyrkiet (Türkiye), 06100
        • Hacettepe Universitesi Tip Fakultesi Hastanesi
      • Edirne, Tyrkiet (Türkiye), 22030
        • Trakya Universitesi Tip Fakultesi
      • Istanbul, Tyrkiet (Türkiye), 34093
        • Istanbul Universitesi Onkoloji Enstitusu
      • Istanbul, Tyrkiet (Türkiye), 34214
        • Medipol Hastanesi
      • Izmir, Tyrkiet (Türkiye), 35040
        • Ege Universitesi Tip Fakultesi Hastanesi
      • Malatya, Tyrkiet (Türkiye), 44280
        • Inonu Universitesi Turgut Ozal Tip Merkezi
      • Miskolc, Ungarn, 3526
        • Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz
      • Szolnok, Ungarn, 5000
        • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet
      • Salzburg, Østrig, 5020
        • Landeskrankenhaus Salzburg
      • Vienna, Østrig, 1090
        • Allgemeines Krankenhaus der Stadt Wien

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Measurable disease based on RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate organ function per protocol-defined criteria.
  • Documentation of results from testing of human papilloma virus (HPV) status for oropharyngeal cancer.
  • Baseline archival tumor specimen available or willing to undergo a prestudy treatment tumor core or excisional biopsy of a tumor lesion not previously irradiated, to obtain the specimen.

Exclusion Criteria:

  • Carcinoma of the nasopharynx, salivary gland, unknown primary origin, or nonsquamous histologies as primary tumors.
  • Disease progression within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
  • Use of protocol-defined prior/concomitant therapy.
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years.
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
  • Known history of or is positive for active hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (defined as HCV RNA [qualitative] is detected).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Pembrolizumab

Pembrolizumab administered intravenously every 3 weeks.

Andre navne:
  • MK-3475
Eksperimentel: Pembrolizumab + Epacadostat

Pembrolizumab administered intravenously every 3 weeks.

Andre navne:
  • MK-3475

Epacadostat administered orally twice daily.

Andre navne:
  • INCB024360
Aktiv komparator: EXTREME

EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil.

Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.

Cisplatin administered intravenously every 3 weeks for </= 6 cycles.

Carboplatin administered intravenously every 3 weeks for </= 6 cycles.

5-Fluorouracil administered intravenously every 3 weeks for </= 6 cycles.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate (ORR) of Pembrolizumab + Epacadostat, Pembrolizumab Monotherapy and the EXTREME Regimen
Tidsramme: Minimum Week 9

ORR was defined as the percentage of participants who had a complete response (CR), disappearance of all target lesions or partial response (PR), >=30% decrease in the sum of the longest diameter of target lesions per RECIST v1.1 by investigator determination. Responses are based on investigator assessments per RECIST 1.1 without confirmation using all available scans.

Minimum Week 9

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab Versus the EXTREME Regimen as Measured by Number of Participants Experiencing Adverse Events (AEs)
Tidsramme: up to approximately 8 years

AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

up to approximately 8 years
Safety and Tolerability of Pembrolizumab + Epacadostat Versus Pembrolizumab Versus the EXTREME Regimen as Measured by Number of Participants Discontinuing Study Treatment Due to AEs
Tidsramme: up to approximately 8 years

AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

up to approximately 8 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Studieleder: Mark Jones, MD, Incyte Corporation

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. december 2017

Primær færdiggørelse (Faktiske)

19. juli 2018

Studieafslutning (Faktiske)

30. oktober 2025

Datoer for studieregistrering

Først indsendt

27. november 2017

Først indsendt, der opfyldte QC-kriterier

27. november 2017

Først opslået (Faktiske)

30. november 2017

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. september 2026

Sidst verificeret

1. september 2026

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner